RCUS
Arcus Biosciences, Inc. NYSE Listed Mar 15, 2018$24.78
Mkt Cap $2.5B
52w Low $7.71
81.2% of range
52w High $28.72
50d MA $23.02
200d MA $18.82
P/E (TTM)
-7.8x
EV/EBITDA
-7.3x
P/B
4.4x
Debt/Equity
0.2x
ROE
-55.9%
P/FCF
-5.3x
RSI (14)
—
ATR (14)
—
Beta
0.86
50d MA
$23.02
200d MA
$18.82
Avg Volume
1.2M
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
3928 Point Eden Way · Hayward, CA 94545 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -0.92 | -1.02 | -10.9% | 26.06 | -4.0% | -0.2% | -4.7% | +2.3% | — | — | — |
| Feb 25, 2026 | AMC | -1.11 | -0.89 | +19.8% | 20.27 | -1.9% | -3.6% | +4.2% | +17.5% | -6.3% | +1.1% | — |
| Oct 28, 2025 | AMC | -1.33 | -1.27 | +4.5% | 19.88 | +0.6% | +2.1% | -0.5% | -2.3% | +3.2% | -2.6% | — |
| Aug 6, 2025 | AMC | -1.14 | -0.08 | +93.4% | 9.49 | +5.1% | -2.2% | -2.4% | +1.1% | +5.6% | +4.0% | — |
| May 6, 2025 | AMC | -1.02 | -1.14 | -11.8% | 8.12 | -8.4% | -1.4% | +6.5% | -2.9% | +6.3% | -1.5% | — |
| Feb 25, 2025 | AMC | -1.17 | -1.03 | +12.0% | 10.24 | +13.2% | -1.0% | -2.6% | +10.2% | -3.6% | -7.7% | — |
| Nov 6, 2024 | AMC | -1.07 | -1.00 | +6.5% | 15.73 | +2.5% | +4.6% | +8.4% | -0.6% | -5.5% | -2.0% | — |
| Aug 8, 2024 | AMC | -1.02 | -1.02 | +0.0% | 13.69 | +8.8% | +14.0% | -4.2% | +4.6% | -6.3% | +7.4% | — |
| May 8, 2024 | AMC | -0.97 | -0.05 | +94.8% | 15.26 | +11.1% | +5.8% | +3.5% | +3.0% | -0.6% | +2.6% | — |
| Feb 21, 2024 | AMC | -1.09 | -1.08 | +0.9% | 16.41 | +3.6% | +19.9% | -0.7% | +0.7% | +2.6% | -5.1% | — |
| Nov 7, 2023 | AMC | -1.12 | -0.94 | +16.1% | 16.45 | +0.5% | -2.7% | -14.2% | -1.5% | -0.8% | +7.1% | — |
| Aug 7, 2023 | AMC | -1.00 | -1.04 | -4.0% | 18.21 | -0.8% | +1.3% | -2.2% | +2.2% | -1.2% | -1.0% | — |
| May 9, 2023 | AMC | -1.06 | -1.09 | -2.8% | 19.40 | -0.7% | -3.0% | -4.2% | +2.6% | +5.6% | -6.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | Wedbush | Maintains | Outperform → Outperform | — | $21.84 | $21.95 | +0.5% | +5.1% | -3.1% | -0.8% | +2.6% | +2.8% |
| Mar 5 | Citigroup | Maintains | Buy → Buy | — | $22.68 | $22.39 | -1.3% | -2.1% | -0.5% | +6.0% | +4.8% | -0.6% |
| Mar 2 | Leerink Partners | Maintains | Outperform → Outperform | — | $20.37 | $20.47 | +0.5% | +17.5% | -6.3% | +1.1% | -2.1% | -0.5% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.37 | $20.47 | +0.5% | +17.5% | -6.3% | +1.1% | -2.1% | -0.5% |
| Feb 12 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $21.36 | $21.58 | +1.0% | -6.6% | -5.2% | +1.7% | +1.0% | +0.3% |
| Jan 13 | Goldman Sachs | Upgrade | Neutral → Buy | — | $21.30 | $22.19 | +4.2% | +6.8% | +8.0% | -11.3% | +0.0% | +0.7% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $23.20 | $22.14 | -4.6% | -8.0% | -1.6% | +1.4% | +6.8% | +8.0% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.14 | $21.15 | -15.9% | -14.4% | +1.8% | +1.3% | +0.4% | -1.3% |
| Nov 28 | BofA Securities | Maintains | Neutral → Neutral | — | $25.56 | $25.81 | +1.0% | +2.1% | +0.0% | -2.6% | +0.8% | -1.4% |
| Oct 30 | Goldman Sachs | Maintains | Neutral → Neutral | — | $20.29 | $20.00 | -1.4% | -0.5% | -2.3% | +3.2% | -2.6% | -0.4% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.88 | $20.00 | +0.6% | +2.1% | -0.5% | -2.3% | +3.2% | -2.6% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $19.88 | $20.00 | +0.6% | +2.1% | -0.5% | -2.3% | +3.2% | -2.6% |
| Oct 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $16.47 | $16.66 | +1.2% | +6.1% | +3.3% | -6.9% | -0.1% | +3.2% |
| Oct 13 | Citigroup | Maintains | Buy → Buy | — | $14.60 | $15.80 | +8.2% | +14.0% | -6.1% | +8.2% | -1.8% | -0.8% |
| Oct 7 | Truist | Maintains | Buy → Buy | — | $14.48 | $14.78 | +2.1% | -3.1% | +7.3% | +0.7% | -3.7% | +14.0% |
| Aug 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $9.49 | $9.97 | +5.1% | -2.2% | -2.4% | +1.1% | +5.6% | +4.0% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.49 | $9.97 | +5.1% | -2.2% | -2.4% | +1.1% | +5.6% | +4.0% |
| May 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.53 | $8.46 | -0.8% | -2.9% | +6.3% | -1.5% | -1.5% | +0.4% |
| May 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $8.01 | $7.96 | -0.6% | +6.5% | -2.9% | +6.3% | -1.5% | -1.5% |
| May 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.12 | $7.44 | -8.4% | -1.4% | +6.5% | -2.9% | +6.3% | -1.5% |
| Apr 23 | Barclays | Maintains | Overweight → Overweight | — | $8.09 | $8.21 | +1.5% | +0.2% | +3.7% | -1.3% | -0.6% | -1.5% |
| Feb 26 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $10.24 | $11.59 | +13.2% | -1.0% | -2.6% | +10.2% | -3.6% | -7.7% |
| Feb 19 | BofA Securities | Maintains | Neutral → Neutral | — | $10.96 | $11.17 | +1.9% | +1.3% | -3.2% | +3.1% | -8.2% | +0.8% |
| Feb 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.10 | $12.80 | -2.3% | -16.3% | +1.3% | -3.2% | +3.1% | -8.2% |
| Feb 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.10 | $12.80 | -2.3% | -16.3% | +1.3% | -3.2% | +3.1% | -8.2% |
| Nov 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $15.29 | $16.23 | +6.1% | +2.9% | +4.6% | +8.4% | -0.6% | -5.5% |
| Oct 25 | Barclays | Maintains | Overweight → Overweight | — | $17.83 | $18.15 | +1.8% | -8.5% | +2.1% | -1.5% | -2.5% | -4.4% |
| Oct 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $17.33 | $17.91 | +3.3% | +2.9% | -8.5% | +2.1% | -1.5% | -2.5% |
| Oct 3 | Wedbush | Maintains | Outperform → Outperform | — | $15.39 | $15.19 | -1.3% | -0.5% | +8.8% | +3.9% | +1.0% | +1.5% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $13.69 | $14.90 | +8.8% | +14.0% | -4.2% | +4.6% | -6.3% | +7.4% |
| Aug 9 | BofA Securities | Maintains | Neutral → Neutral | — | $13.69 | $14.90 | +8.8% | +14.0% | -4.2% | +4.6% | -6.3% | +7.4% |
| Jul 8 | Barclays | Maintains | Overweight → Overweight | — | $14.12 | $14.19 | +0.5% | -2.0% | +1.7% | -1.0% | +7.0% | +1.3% |
| Jun 24 | Truist | Maintains | Buy → Buy | — | $16.35 | $16.50 | +0.9% | +0.4% | -3.5% | -4.2% | +0.1% | +0.4% |
| Jun 3 | Citigroup | Maintains | Buy → Buy | — | $15.07 | $15.82 | +5.0% | +5.1% | +1.0% | +1.8% | -2.3% | -2.5% |
| May 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.71 | $17.00 | +1.7% | +3.0% | -0.6% | +2.6% | -0.5% | -3.2% |
| May 9 | Wedbush | Maintains | Outperform → Outperform | — | $15.26 | $16.96 | +11.1% | +5.8% | +3.5% | +3.0% | -0.6% | +2.6% |
| Mar 25 | Truist | Maintains | Buy → Buy | — | $16.43 | $16.47 | +0.2% | +0.2% | +1.1% | +9.4% | +3.7% | -2.1% |
| Feb 22 | Wedbush | Maintains | Outperform → Outperform | — | $16.41 | $17.00 | +3.6% | +19.9% | -0.7% | +0.7% | +2.6% | -5.1% |
| Jan 30 | Wedbush | Maintains | Outperform → Outperform | — | $15.30 | $16.11 | +5.3% | +2.7% | -3.7% | +4.7% | -5.6% | +1.7% |
| Jan 30 | Mizuho | Maintains | Buy → Buy | — | $15.30 | $16.11 | +5.3% | +2.7% | -3.7% | +4.7% | -5.6% | +1.7% |
| Jan 17 | Wedbush | Maintains | Outperform → Outperform | — | $16.90 | $16.82 | -0.5% | +0.6% | -3.7% | -6.3% | -1.5% | +2.2% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.54 | $13.38 | -1.2% | -0.8% | +7.1% | +1.1% | -3.4% | +3.1% |
| Nov 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.45 | $16.54 | +0.5% | -2.7% | -14.2% | -1.5% | -0.8% | +7.1% |
| Oct 3 | Mizuho | Maintains | Buy → Buy | — | $17.29 | $17.24 | -0.3% | -1.3% | -7.3% | +3.5% | +2.0% | -1.8% |
| Sep 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $20.79 | $20.54 | -1.2% | +2.2% | -2.5% | -2.3% | +1.6% | -3.3% |
| Sep 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.50 | $22.39 | -0.5% | -5.4% | +0.5% | -2.8% | +2.2% | -2.5% |
| Sep 6 | Truist | Maintains | Buy → Buy | — | $21.99 | $22.19 | +0.9% | +2.3% | -5.4% | +0.5% | -2.8% | +2.2% |
| Sep 5 | BofA Securities | Maintains | Neutral → Neutral | — | $21.20 | $21.00 | -0.9% | +3.7% | +2.3% | -5.4% | +0.5% | -2.8% |
| Aug 24 | Citigroup | Maintains | Buy → Buy | — | $23.03 | $23.00 | -0.1% | -0.5% | -1.4% | -3.7% | -7.3% | -0.4% |
| Aug 23 | Mizuho | Maintains | Buy → Buy | — | $18.81 | $23.22 | +23.4% | +22.4% | -0.5% | -1.4% | -3.7% | -7.3% |
No insider trades available.
8-K · 2.02
!! High
Arcus Biosciences, Inc. -- 8-K 2.02: Earnings Results
Arcus Biosciences reported first-quarter 2026 financial results, providing investors with updated information on the company's operational performance and financial condition during the period.
May 5
8-K · 8.01
!! High
Arcus Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Gilead's acquisition of Arcus Biosciences faces setback as the STAR-121 trial of domvanalimab and zimberelimab failed to meet futility analysis criteria for first-line lung cancer treatment.
Apr 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
# Analysis: RCUS Executive Change
Rcus's executive departure increases uncertainty about strategic direction and operational continuity, potentially pressuring the stock until management stability is demonstrated and a replacement plan is announced.
Mar 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A life sciences-focused executive with deep investment banking expertise joined one of these companies, potentially signaling strategic M&A activity or capital-raising plans ahead.
Mar 23
8-K
Arcus Biosciences, Inc. -- 8-K Filing
Arcus Biosciences reported 2025 financial results and shared updated ASCO GU data supporting casdatifan's potential as a best-in-class HIF-2α inhibitor for cancer treatment.
Feb 25
Data updated apr 26, 2026 10:08pm
· Source: massive.com